Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6,452 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Mita K, et al. Among authors: tanaka n. Cancers (Basel). 2024 Jan 24;16(3):508. doi: 10.3390/cancers16030508. Cancers (Basel). 2024. PMID: 38339260 Free PMC article.
Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, Ishibashi K, Kamiyama M, Kawai N, Enokida H, Shima T, Takahara S. Izumi K, et al. Among authors: tanaka n. BMC Cancer. 2017 Oct 10;17(1):677. doi: 10.1186/s12885-017-3661-2. BMC Cancer. 2017. PMID: 29017493 Free PMC article. Clinical Trial.
Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients.
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M; Japanese Urological Oncology Group (JUOG). Shiota M, et al. Among authors: tanaka n. Cancer Sci. 2021 Apr;112(4):1524-1533. doi: 10.1111/cas.14722. Epub 2021 Feb 13. Cancer Sci. 2021. PMID: 33159829 Free PMC article.
Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.
Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group. Shiota M, et al. Among authors: tanaka n. Cancer Sci. 2021 Sep;112(9):3616-3626. doi: 10.1111/cas.15038. Epub 2021 Jul 10. Cancer Sci. 2021. PMID: 34145921 Free PMC article.
Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden.
Nagumo Y, Onozawa M, Kojima T, Terada N, Shiota M, Mitsuzuka K, Yasumoto H, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Saito T, Yokomizo A, Kohei N, Tabata KI, Takahashi A, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H; Japanese Urological Oncology Group (JUOG). Nagumo Y, et al. Int J Urol. 2022 May;29(5):398-405. doi: 10.1111/iju.14793. Epub 2022 Jan 25. Int J Urol. 2022. PMID: 35080069
Potential effectiveness of local radiotherapy for extending survival and reducing symptomatic local events in patients with de novo metastatic prostate cancer.
Terada N, Mizowaki T, Saito T, Yokomizo A, Kohei N, Tabata KI, Shiota M, Takahashi A, Shimazui T, Goto T, Hashimoto Y, Fujii M, Tomida R, Sakurai T, Hashimoto K, Kawamura S, Teraoka S, Sakamoto S, Kimura T, Kamiyama M, Narita S, Tanaka N, Kato T, Kato M, Osawa T, Kojima T, Inoue T, Sugimoto M, Nishiyama H, Kamoto T; Japanese Urological Oncology Group. Terada N, et al. Among authors: tanaka n. BJUI Compass. 2020 Aug 30;1(5):165-173. doi: 10.1002/bco2.35. eCollection 2020 Nov. BJUI Compass. 2020. PMID: 35475210 Free PMC article.
Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial.
Izumi K, Shima T, Mita K, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Izumi K, et al. Among authors: tanaka n. Eur Urol Open Sci. 2022 May 19;41:16-23. doi: 10.1016/j.euros.2022.04.016. eCollection 2022 Jul. Eur Urol Open Sci. 2022. PMID: 35813251 Free PMC article.
Impact of Complete Surgical Resection of Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma in the Era of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors.
Shimizu T, Miyake M, Nishimura N, Yoshida T, Itami Y, Tachibana A, Omori C, Oda Y, Kohashi M, Tomizawa M, Onishi K, Hori S, Morizawa Y, Dotoh D, Nakai Y, Torimoto K, Tanaka N, Fujimoto K. Shimizu T, et al. Among authors: tanaka n. Cancers (Basel). 2024 Feb 19;16(4):841. doi: 10.3390/cancers16040841. Cancers (Basel). 2024. PMID: 38398232 Free PMC article.
Nationwide Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 Seed Implantation (J-POPS): first analysis on survival.
Ito K, Saito S, Yorozu A, Kojima S, Kikuchi T, Higashide S, Aoki M, Koga H, Satoh T, Ohashi T, Nakamura K, Katayama N, Tanaka N, Nakano M, Shigematsu N, Dokiya T, Fukushima M; J-POPS Investigators. Ito K, et al. Among authors: tanaka n. Int J Clin Oncol. 2018 Dec;23(6):1148-1159. doi: 10.1007/s10147-018-1309-0. Epub 2018 Jun 22. Int J Clin Oncol. 2018. PMID: 29934842
6,452 results